Nitrate and Brain Insulin-Sensitivity (NO-BRAINS)

Maastricht University Medical Centre (MUMC)

Status

Completed

Conditions

Brain Insulin-sensitivity

Vascular Function

Nitrate

Treatments

Dietary Supplement: Potassium nitrate

Dietary Supplement: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT04700241

METC 20-0.78

Details and patient eligibility

About

Disturbances in brain insulin-sensitivity are not only observed in abdominal obesity and type 2 diabetes mellitus (T2D), but also during brain aging and in dementia. Inorganic nitrate may improve brain insulin-sensitivity, which can be quantified by measuring the gray-matter cerebral blood flow (CBF) response to intranasally administered insulin, through beneficial effects on brain vascular function. Therefore, we now hypothesize that inorganic nitrate, which can be found in several vegetables such as beetroot, improves brain insulin-sensitivity, as assessed by the gray-matter CBF response to intranasally administered insulin, in abdominally obese men.

Enrollment

18 patients

Sex

Male

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Men;
Aged between 18 - 60 years;
Waist circumference > 102 cm (abdominally obese);
Fasting plasma glucose ≤ 7.0 mmol/L;
Fasting serum total cholesterol ≤ 8.0 mmol/L;
Systolic blood pressure < 160 mmHg and diastolic blood pressure < 100 mmHg;
Stable body weight (weight gain or loss < 3 kg in the past three months);
Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study;
Willingness not to use antibacterial mouth wash or toothpaste, chewing-gum and tongue-scraping a week before the study;
No difficult venipuncture as evidenced during the screening visit.

Exclusion criteria

Women;
Left-handedness;
Current smoker, or smoking cessation < 12 months;
Diabetic patients;
Familial hypercholesterolemia;
Abuse of drugs;
More than 3 alcoholic consumptions per day;
Use of products or dietary supplements known to interfere with the main outcomes as judged by the principal investigators;
Use medication to treat blood pressure, lipid or glucose metabolism;
Pharmacological treatment advised based on the Dutch general practitioners' association (NHG) for cardiovascular risk management;
Use of an investigational product within another biomedical intervention trial within the previous 1-month;
Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis;
Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident;
Specific contra-indications for MRI imaging, including pacemakers, surgical clips/material in body, metal splinters in eye, claustrophobia, or tattoos in the facial area, such as permanent make-up.